Eagle Global Advisors LLC Makes New Investment in Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Key Points

• Eagle Global Advisors LLC acquired 209,295 shares of Genmab A/S, valued at approximately $4.1 million, indicating increased institutional interest in the company.
• Analysts have recently upgraded Genmab A/S ratings, with Truist Financial raising the price target from $45 to $46 and a consensus rating of “Moderate Buy” among equities research analysts.
• Genmab A/S reported earnings of $0.54 per share for the last quarter, surpassing estimates and indicating strong potential for growth, with anticipated earnings of 1.45 per share for the current year.

Eagle Global Advisors LLC acquired a new stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 209,295 shares of the company's stock, valued at approximately $4,098,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Headlands Technologies LLC raised its stake in Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after acquiring an additional 1,464 shares during the period. Barclays PLC grew its holdings in Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in Genmab A/S during the 4th quarter valued at about $60,000. Advisors Preferred LLC purchased a new position in Genmab A/S during the 1st quarter valued at about $84,000. Finally, Aquatic Capital Management LLC purchased a new position in Genmab A/S during the 4th quarter valued at about $114,000. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on GMAB. Wall Street Zen raised Genmab A/S from a "hold" rating to a "buy" rating in a report on Monday, July 28th. Truist Financial lifted their target price on Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $37.80.

Genmab A/S Stock Performance

Genmab A/S stock traded up $0.80 during mid-day trading on Wednesday, hitting $22.67. 827,040 shares of the company traded hands, compared to its average volume of 1,134,931. Genmab A/S Sponsored ADR has a one year low of $17.24 and a one year high of $27.94. The stock has a market cap of $14.54 billion, a price-to-earnings ratio of 11.39, a price-to-earnings-growth ratio of 6.42 and a beta of 0.95. The stock has a fifty day moving average price of $21.75 and a 200-day moving average price of $20.88.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.15. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The business had revenue of $925.00 million during the quarter, compared to analyst estimates of $5.77 billion. Sell-side analysts predict that Genmab A/S Sponsored ADR will post 1.45 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.